Publications

  1. von Roemeling C, Ferreri AJM, Soussain C, Tun HW, Grommes C. Targets and treatments in primary CNS lymphoma. Leuk Lymphoma. 2024 Apr 24; 1-13 [Epub ahead of print]
    View PubMed
  2. Chohan KL, Young JR, Lester S, Moustafa MA, Rosenthal A, Tun HW, Hoppe BS, Johnston PB, Micallef IN, Habermann TM, Ansell SM. End-of-treatment PET in early-stage Hodgkin lymphoma: valuable in addition to interim PET. Haematologica 2023 Jun 1; 108 (6):1697-1701 Epub 2023 June 01
    View PubMed
  3. Huntington SF, Schuster SJ, Ding W, Koehler AB, Brander DM, Rosenthal AC, Leis JF, Tun HW, Alhaj Moustafa M, Moustafa MA, Iqbal M, He W, Kearney AS, McKinlay TP, Gui M, Mato AR. DTRMWXHS-12, a novel Bruton tyrosine kinase inhibitor, in combination with everolimus and pomalidomide in patients with relapsed/refractory lymphomas: An open-label, multicenter, phase 1a/1b study. Am J Hematol. 2023 May; 98 (5):739-749 Epub 2023 Mar 07
    View PubMed
  4. Von Roemeling CA, Doonan BP, Klippel K, Schultz D, Hoang-Minh L, Trivedi V, Li C, Russell RA, Kanumuri RS, Sharma A, Tun HW, Mitchell DA. Oral IRAK-4 Inhibitor CA-4948 Is Blood-Brain Barrier Penetrant and Has Single-Agent Activity against CNS Lymphoma and Melanoma Brain Metastases. Clin Cancer Res. 2023 May 1; 29 (9):1751-1762
    View PubMed
  5. Alhaj Moustafa M, Borah BJ, Moriarty JP, Dholakia R, Jiang L, Li K, Witzig TE, Hoppe BS, Peterson J, Cerhan JR, Tun HW. Yttrium-90 Ibritumomab Tiuxetan is Cost-Effective Compared to Bendamustine + Rituximab in Low-grade Lymphomas. Clin Lymphoma Myeloma Leuk. 2023 Apr; 23 (4):259-265 Epub 2023 Jan 26
    View PubMed
  6. Tun AM, Wang Y, Matin A, Inwards DJ, Habermann TM, Micallef I, Johnston PB, Porrata L, Paludo J, Bisneto JV, Rosenthal A, Tun HW, Cerhan JR, Witzig TE, Nowakowski GS, Ansell SM. Outcomes of Patients With Classic Hodgkin Lymphoma Who Relapsed After Autologous Stem Cell Transplant. Hemasphere. 2023 Apr; 7 (4):e869 Epub 2023 Apr 04
    View PubMed
  7. Iqbal M, Jiang L, Li KD, Moustafa MA, Kimbrough EO, Ansell SM, Tun HW. Poly-lymphomatous Syndrome With Concurrent or Sequential Hodgkin and Non-Hodgkin lymphoma. Clin Lymphoma Myeloma Leuk. 2023 Feb; 23 (2):138-144 Epub 2022 Nov 18
    View PubMed
  8. Parrondo RD, Iqbal M, Von Roemeling R, Von Roemeling C, Tun HW. IRAK-4 inhibition: emavusertib for the treatment of lymphoid and myeloid malignancies. Front Immunol. 2023; 14:1239082 Epub 2023 Oct 26
    View PubMed
  9. Plante MM, Kimbrough EO, Agarwal AK, Jiang L, Bourgeois K, Stamper GC, Stewart MW, Tun HW. Hyperviscosity Syndrome Induced Bilateral Visual and Auditory Impairment in Therapy Resistant Waldenstrom Macroglobulinemia with MYD88 and CXCR4 Mutations. J Blood Med. 2023; 14:639-648 Epub 2023 Dec 15
    View PubMed
  10. Davis J, Kimbrough EO, Alhaj Moustafa M, Jiang L, Gupta V, Parent E, Tun HW. Successful CNS-Centric Therapeutic Management and Genomic Profiling of Primary Cranial Vault Diffuse Large B-Cell Lymphoma. J Blood Med. 2023; 14:49-55 Epub 2023 Jan 22
    View PubMed
  11. Kimbrough EO, Gupta V, Jiang L, Tun HW. Successful Anatomy Adapted Therapeutic Management and Genetic Profiling of Primary Pituitary Diffuse Large B-Cell Lymphoma. Blood Lymphat Cancer. 2023; 13:25-32 Epub 2023 July 28
    View PubMed
  12. Fournier LL, Kimbrough EO, Alhaj Moustafa M, Li K, Iqbal M, Gupta V, Tun HW. Multiply Relapsed Secondary CNS Non-Germinal Center Diffuse Large B-Cell Lymphoma Successfully Treated with CNS-Centric Therapy. J Blood Med. 2023; 14:455-461. Epub 2023 Aug 16.
    View PubMed
  13. Wang J, Baidoun F, Tun HW, Alhaj Moustafa M. 90Yttrium Ibritumomab Tiuxetan (Zevalin) for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: A Report of 5 Cases. Blood Lymphat Cancer. 2023; 13:59-65. Epub 2023 Oct 03.
    View PubMed
  14. Wolf EB, Li D, Fernandez AJ, Gardner LB, Rivera CE, Wysokinska EM, Shaikh ME, Tun HW, Roy V, Alhaj Moustafa M. Acquired Factor VII Deficiency Associated With Chronic Myeloid Leukemia Blast Crisis. J Investig Med High Impact Case Rep. 2023 Jan-Dec; 11:23247096231209543.
    View PubMed
  15. Iqbal M, Bansal R, Yassine F, Gandhi S, Rosenthal A, Moustafa MA, Li Z, Craver EC, Mohty R, Murthy H, Ayala E, Tun H, Munoz J, Castro J, Lin Y, Kharfan-Dabaja MA. Impact of Rituximab and Corticosteroids on Late Cytopenias Post-Chimeric Antigen Receptor T Cell Therapy. Transplant Cell Ther. 2022 Oct; 28 (10):668.e1-668.e6 Epub 2022 July 14
    View PubMed
  16. Seegobin K, Li Z, Alhaj Moustafa M, Majeed U, Wang J, Jiang L, Kuhlman J, Menke D, Li K, Kharfan-Dabaja MA, Ayala E, Iqbal M, Nowakowski GS, Habermann TM, Witzig TE, Johnston P, Thompson C, Ansell S, Tun HW. Clinical characteristics, prognostic indicators, and survival outcomes in intravascular lymphoma: Mayo Clinic experience (2003-2018). Am J Hematol. 2022 Sep; 97 (9):1150-1158 Epub 2022 July 06
    View PubMed
  17. Alhaj Moustafa M, Peterson J, Hoppe BS, Jiang J, Wiseman GA, Witzig TE, Tun HW. Real World Long-term Follow-up Experience with Yttrium-90 ibritumomab tiuxetan in Previously Untreated Patients with Low-Grade Follicular Lymphoma and Marginal Zone Lymphoma. Clin Lymphoma Myeloma Leuk. 2022 Aug; 22 (8):618-625 Epub 2022 Mar 17
    View PubMed
  18. Kuhlman JJ, Moustafa MA, Jiang L, Iqbal M, Seegobin K, Wolcott Z, Ayala E, Ansell S, Rosenthal A, Paludo J, Micallef I, Johnston P, Inwards D, Habermann T, Kharfan-Dabaja M, Witzig TE, Nowakowski GS, Tun HW. Leukemic High Grade B Cell Lymphoma is Associated With MYC Translocation, Double Hit/Triple Hit Status, Transformation, and CNS Disease Risk: The Mayo Clinic Experience. Clin Lymphoma Myeloma Leuk. 2022 Aug; 22 (8):e815-e825 Epub 2022 Apr 14
    View PubMed
  19. Chohan KL, Young JR, Lester S, Alhaj Moustafa M, Rosenthal A, Tun HW, Hoppe BS, Johnston PB, Micallef IN, Habermann TM, Ansell SM. A real-world study of combined modality therapy for early-stage Hodgkin lymphoma: too little treatment impacts outcome. Blood Adv. 2022 Jul 26; 6 (14):4241-4250
    View PubMed
  20. Baidoun F, Moustafa MA, Tun HW, Hill BT. Clinical Characteristics and Survival Outcomes of Primary Effusion Lymphoma: A National Cancer Database Study. Clin Lymphoma Myeloma Leuk. 2022 Jul; 22 (7):e485-e494 Epub 2022 Jan 14
    View PubMed
  21. Iqbal M, Castano YG, Paludo J, Rosenthal A, Li Z, Beltran M, Moustafa MA, Inwards D, Porrata L, Micallef I, Bisneto JCV, Johnston P, Ansell SM, Reeder C, Murthy H, Roy V, Foran J, Tun HW, Kharfan-Dabaja MA, Ayala E. Impact of Cell of Origin on Outcomes After Autologous Hematopoietic Cell Transplant in Diffuse Large B-Cell Lymphoma. Clin Lymphoma Myeloma Leuk. 2022 Feb; 22 (2):e89-e95 Epub 2021 Aug 31
    View PubMed
  22. Kase AM, Bullock C, Parrondo R, Alhaj Moustafa M, Iqbal M, Li KD, Parent EE, Tun H. Neuropsychiatric Manifestations of Lymphoma-Associated Cerebral Glucose Hypometabolism Can Be Reversed by Intensive Glucose Supplementation. Blood Lymphat Cancer. 2022; 12:17-21 Epub 2022 Mar 23
    View PubMed
  23. Saifi O, Breen WG, Lester SC, Rule WG, Stish B, Rosenthal A, Munoz J, Herchko SM, Murthy HS, Lin Y, Bansal R, Hathcock MA, Bennani NN, Paludo J, Wang Y, Khurana A, Bisneto JCV, Johnston PB, Ansell SM, Iqbal M, Tun H, Ayala E, Kharfan-Dabaja MA, Hoppe BS, Peterson JL. Does bridging radiation therapy affect the pattern of failure after CAR T-cell therapy in non-Hodgkin lymphoma? Radiother Oncol. 2022 Jan; 166:171-179. Epub 2021 Dec 07.
    View PubMed
  24. Wang J, Alhaj Moustafa M, Kuhlman JJ, Seegobin K, Jiang L, Gupta V, Tun HW. Intravascular Large B Cell Lymphoma with CNS Involvement Successfully Treated with High-Dose Methotrexate and High-Dose Ara-C Based CNS-Directed Chemoimmunotherapy Alternating with Anthracycline Based Chemoimmunotherapy. Blood Lymphat Cancer. 2022; 12:47-54 Epub 2022 May 25
    View PubMed
  25. Kuhlman JJ, Alhaj Moustafa M, Jiang L, Wang J, Gupta V, Tun HW. Long-Term Survival with Ibrutinib Therapy in Elderly Patients with Newly Diagnosed Primary Central Nervous System Lymphoma. Blood Lymphat Cancer. 2022; 12:23-29 Epub 2022 Apr 14
    View PubMed
  26. Kimbrough EO, Jiang L, Parent EE, Bourgeois K, Alhaj Moustafa M, Tun HW, Iqbal M. Primary Bone Marrow Lymphoma: De Novo and Transformed Subtypes. J Blood Med. 2022; 13:663-671. Epub 2022 Nov 14.
    View PubMed
  27. Saifi O, Lester SC, Rule W, Stish BJ, Stafford S, Pafundi DH, Jiang L, Menke D, Moustafa MA, Rosenthal A, Sher T, Ernesto A, Tun HW, Hoppe BS, Peterson JL. Comparable Efficacy of Reduced Dose Radiation Therapy for the Treatment of Early Stage Gastric Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue. Adv Radiat Oncol. 2021 Jul-Aug; 6 (4):100714 Epub 2021 May 08
    View PubMed
  28. Melody M, Gandhi S, Rahman ZA, Lengerke-Diaz P, Gannon N, Rosenthal A, Truong T, Novo M, Brandes E, Lange G, Estby B, Johnston P, Ansell S, Bennani NN, Paludo J, Bisneto JV, Ayala E, Tun HW, Murthy HS, Roy V, Foran J, Castro J, Lin Y, Kharfan-Dabaja MA. Impact of hypoalbuminemia on the prognosis of relapsed/refractory B-cell lymphoma treated with axicabtagene ciloleucel. Eur J Haematol. 2021 Jul; 107 (1):48-53 Epub 2021 Apr 15
    View PubMed
  29. Melody M, Rahman ZA, Saunders H, Diaz PL, Gannon N, Rosenthal A, Ayala E, Tun HW, Murthy H, Roy V, Foran J, Castro JE, Guru P, Kharfan-Dabaja MA. C-reactive protein and ferritin levels and length of intensive care unit stay in patients with B-cell lymphomas treated with axicabtagene ciloleucel. Hematol Oncol Stem Cell Ther. 2021 Jun; 14 (2):141-146 Epub 2020 Oct 13
    View PubMed
  30. Kuhlman JJ, Alhaj Moustafa M, Tun AJ, Menke DM, Tun HW, Jiang L. Primary age-related EBV-associated effusion-based lymphoma successfully treated with rituximab and thoracentesis. Clin Case Rep. 2021 May; 9 (5):e03971 Epub 2021 Apr 04
    View PubMed
  31. Seegobin K, Moustafa MA, Gannon N, Keller K, Hastings J, Gupta V, Tun HW, Jiang L. Successful treatment of IgG4-related hypertrophic pachymeningitis with induction rituximab and dexamethasone followed by maintenance rituximab. Clin Case Rep. 2021 Mar; 9 (3):1610-1614 Epub 2021 Jan 27
    View PubMed
  32. Bojanini L, Jiang L, Tun AJ, Ayala E, Menke DM, Hoppe B, Kharfan-Dabaja MA, Tun HW, Alhaj Moustafa M. Outcomes of Hepatosplenic T-Cell Lymphoma: The Mayo Clinic Experience. Clin Lymphoma Myeloma Leuk. 2021 Feb; 21 (2):106-112.e1 Epub 2020 Oct 05
    View PubMed
  33. Seegobin K, Alhaj Moustafa M, Jiang L, Tun HW. Successful Non-Transplant Treatment of Double Hit Richter Transformation with Long-Term Remission. Blood Lymphat Cancer. 2021; 11:67-72 Epub 2021 Sept 22
    View PubMed
  34. Alhaj Moustafa M, Jiang L, Kuhlman JJ, Jones J, Lou Y, Sokumbi O, Tun HW. BRAF p.V600E associated poly-neoplastic syndrome. Rare Tumors. 2021; 13:20363613211012929 Epub 2021 Apr 27
    View PubMed
  35. Kuhlman J, Alhaj Moustafa M, Jiang L, Tun HW. Primary HHV-8 (-) Effusion-Based Non-Germinal Center B Cell Diffuse Large B Cell Lymphoma Successfully Treated with Standard Anthracycline-Based Chemoimmunotherapy. J Blood Med. 2021; 12:833-838 Epub 2021 Sept 09
    View PubMed
  36. Kuhlman JJ, Alhaj Moustafa M, Gupta V, Jiang L, Tun HW. Primary Cauda Equina Lymphoma Treated with CNS-Centric Approach: A Case Report and Literature Review. J Blood Med. 2021; 12:645-652 Epub 2021 July 21
    View PubMed
  37. Seegobin K, Alhaj Moustafa M, Majeed U, Ray JC, Shaikh M, Jiang L, Tun HW. Macrophage Activation Led Acute Heart Failure Managed Successfully with Immunosuppression. J Blood Med. 2021; 12:1037-1043 Epub 2021 Dec 07
    View PubMed
  38. Seegobin K, Alhaj Moustafa M, Fischer D, Keller K, Hastings J, Kharfan-Dabaja MA, Ayala E, Gupta V, Tun HW, Jiang L. Systemic ALK-positive anaplastic large cell lymphoma with bilateral optic neurolymphomatosis resulting in permanent blindness. Clin Case Rep. 2020 Dec; 8 (12):2629-2633 Epub 2020 Aug 14
    View PubMed
  39. Caulfield TR, Hayes KE, Qiu Y, Coban M, Seok Oh J, Lane AL, Yoshimitsu T, Hazlehurst L, Copland JA, Tun HW. A Virtual Screening Platform Identifies Chloroethylagelastatin A as a Potential Ribosomal Inhibitor. Biomolecules. 2020 Oct 5; 10 (10) Epub 2020 Oct 05
    View PubMed
  40. Parrondo RD, Reljic T, Iqbal M, Ayala E, Tun HW, Kharfan-Dabaja MA, Kumar A, Murthy HS. Efficacy of Autologous and Allogeneic Hematopoietic Cell Transplantation in Waldenstrom Macroglobulinemia: A Systematic Review and Meta-analysis. Clin Lymphoma Myeloma Leuk. 2020 Oct; 20 (10):e694-e711 Epub 2020 June 02
    View PubMed
  41. Melody M, Parrondo R, Alhaj Moustafa M, Wu K, Menke D, Seim L, Tun HW. Follicular lymphoma associated paraneoplastic myositis. Clin Case Rep. 2020 Oct; 8 (10):2003-2006 Epub 2020 July 23
    View PubMed
  42. Dholaria B, Vanegas YAM, Diehl N, Spaulding AC, Visscher S, Tun HW, Ailawadhi S, Vishnu P. Cost Analysis of R-CHOP Versus Dose-Adjusted R-EPOCH in Treatment of Diffuse Large B-Cell Lymphoma with High-Risk Features. Clin Hematol Int. 2020 Sep; 2(3):117-124. Epub 2020 Apr 23.
    View PubMed
  43. Drake RR, McDowell C, West C, David F, Powers TW, Nowling T, Bruner E, Mehta AS, Angel PM, Marlow LA, Tun HW, Copland JA. Defining the human kidney N-glycome in normal and cancer tissues using MALDI imaging mass spectrometry. J Mass Spectrom. 2020 Apr; 55 (4):e4490 Epub 2020 Jan 21
    View PubMed
  44. Iqbal M, Reljic T, Ayala E, Sher T, Murthy H, Roy V, Foran J, Tun H, Kumar A, Kharfan-Dabaja MA. Efficacy of Allogeneic Hematopoietic Cell Transplantation in Cutaneous T Cell Lymphoma: Results of a Systematic Review and Meta-Analysis. Biol Blood Marrow Transplant. 2020 Jan; 26 (1):76-82 Epub 2019 Sept 05
    View PubMed
  45. Khurana S, Melody ME, Ketterling RP, Peterson JF, Luoma IM, Vazmatzis G, Tun HW, Foran JM, Jiang L. Molecular and phenotypic characterization of an early T-cell precursor acute lymphoblastic lymphoma harboring PICALM-MLLT10 fusion with aberrant expression of B-cell antigens. Cancer Genet. 2020 Jan; 240:40-44 Epub 2019 Nov 09
    View PubMed
  46. Kharfan-Dabaja MA, Jain MD, Aulakh S, Ayala E, Zubair AC, Tun HW, Liu HD, Locke FL, Chavez JC. Obinutuzumab as bridging therapy for successful manufacturing of axicabtagene ciloleucel for transformed follicular lymphoma with circulating cells. Am J Hematol 2019 Sep; 94 (9):E245-E247 Epub 2019 June 18
    View PubMed
  47. Dholaria BR, Kumar A, Azzuqua AG, Nishihori T, Kharfan-Dabaja MA, Tun HW, Ayala E. Autologous Stem Cell Transplantation in Central Nervous System Lymphoma: A Multicenter Retrospective Series and a Review of the Literature. Clin Lymphoma Myeloma Leuk. 2019 Jun; 19 (6):e273-e280 Epub 2019 Feb 26
    View PubMed
  48. Bastea LI, Liou GY, Pandey V, Fleming AK, von Roemeling CA, Doeppler H, Li Z, Qiu Y, Edenfield B, Copland JA, Tun HW, Storz P. Pomalidomide Alters Pancreatic Macrophage Populations to Generate an Immune-Responsive Environment at Precancerous and Cancerous Lesions. Cancer Res. 2019 Apr 1; 79 (7):1535-1548 Epub 2019 Jan 29
    View PubMed
  49. Grommes C, Nayak L, Tun HW, Batchelor TT. Introduction of novel agents in the treatment of primary CNS lymphoma. Neuro Oncol. 2019 Feb 19; 21 (3):306-313
    View PubMed
  50. Litzow MR, Wang XV, Carroll MP, Karp JE, Ketterling RP, Zhang Y, Kaufmann SH, Lazarus HM, Luger SM, Paietta EM, Pratz KW, Tun HW, Altman JK, Broun ER, Rybka WB, Rowe JM, Tallman MS. A randomized trial of three novel regimens for recurrent acute myeloid leukemia demonstrates the continuing challenge of treating this difficult disease. Am J Hematol. 2019 Jan; 94 (1):111-117 Epub 2018 Nov 15
    View PubMed
  51. Tun HW, Johnston PB, DeAngelis LM, Atherton PJ, Pederson LD, Koenig PA, Reeder CB, Omuro AMP, Schiff D, O'Neill B, Pulido J, Jaeckle KA, Grommes C, Witzig TE. Phase 1 study of pomalidomide and dexamethasone for relapsed/refractory primary CNS or vitreoretinal lymphoma. Blood. 2018 Nov 22; 132 (21):2240-2248 Epub 2018 Sept 27
    View PubMed
  52. Dholaria BR, Hammond WA, Roy V, Sher T, Vishnu P, Soyano A, Finn LE, Tun H. Allogeneic hematopoietic cell transplant for relapsed-refractory, marginal zone lymphoma: a single-center experience. Leuk Lymphoma 2018 Nov; 59 (11):2727-2730 Epub 2018 Mar 23
    View PubMed
  53. Qiu Y, Li Z, Pouzoulet F, Vishnu P, Copland JA 3rd, Knutson KL, Soussain C, Tun HW. Immune checkpoint inhibition by anti-PDCD1 (anti-PD1) monoclonal antibody has significant therapeutic activity against central nervous system lymphoma in an immunocompetent preclinical model. Br J Haematol 2018 Nov; 183 (4):674-678 Epub 2017 Oct 26
    View PubMed
  54. May JM, Waddle MR, Miller DH, Stross WC, Kaleem TA, May BC, Miller RC, Jiang L, Strong GW, Trifiletti DM, Chaichana KL, Reimer R, Tun HW, Peterson JL. Primary histiocytic sarcoma of the central nervous system: a case report with platelet derived growth factor receptor mutation and PD-L1/PD-L2 expression and literature review. Radiat Oncol. 2018 Sep 5; 13 (1):167 Epub 2018 Sept 05
    View PubMed
  55. Qiu Y, Li Z, Copland JA, Mehrling T, Tun HW. Combined alkylation and histone deacetylase inhibition with EDO-S101 has significant therapeutic activity against brain tumors in preclinical models. Oncotarget. 2018 Jun 15; 9 (46):28155-28164 Epub 2018 June 15
    View PubMed
  56. von Roemeling CA, Caulfield TR, Marlow L, Bok I, Wen J, Miller JL, Hughes R, Hazlehurst L, Pinkerton AB, Radisky DC, Tun HW, Kim YSB, Lane AL, Copland JA. Accelerated bottom-up drug design platform enables the discovery of novel stearoyl-CoA desaturase 1 inhibitors for cancer therapy. Oncotarget. 2018 Jan 2; 9 (1):3-20 Epub 2017 Oct 06
    View PubMed
  57. Iqbal M, Saleem R, Ahmed S, Jani P, Alvarez S, Tun HW. Successful Antimicrobial Treatment of Phlegmonous Gastritis: A Case Report and Literature Review. Case Rep Hematol. 2018; 2018:8274732 Epub 2018 Sept 16
    View PubMed
  58. Baldeo CM, Rivera CE, Tun HW, Vishnu P. Pharmacokinetics-based clinical management of acquired von Willebrand syndrome: a case report. J Blood Med. 2018; 9:9-13 Epub 2018 Jan 19
    View PubMed
  59. Menke JR, Vasmatzis G, Murphy S, Yang L, Menke DM, Tun HW, King RL, Smoley SA, Ketterling RP, Sukov WR. Mantle cell lymphoma with a novel t(11;12)(q13;p11.2): a proposed alternative mechanism of CCND1 up-regulation. Hum Pathol. 2017 Jun; 64:207-212 Epub 2017 Jan 27
    View PubMed
  60. Hammond WA, Swaika A, Menke D, Tun HW. Hairy Cell Lymphoma: A Potentially Under-Recognized Entity. Rare Tumors. 2017 Mar 24; 9 (1):6518 Epub 2017 Mar 28
    View PubMed
  61. Yoshimitsu T, Tun HW. Compounds, compositions, and methods of agelastatin alkaloids: patent evaluation of WO2015042239 (A1). Expert Opin Ther Pat. 2017 Feb; 27: (2)113-119.
    View PubMed
  62. Qie Y, Yuan H, von Roemeling CA, Chen Y, Liu X, Shih KD, Knight JA, Tun HW, Wharen RE, Jiang W, Kim BY. Corrigendum: Surface modification of nanoparticles enables selective evasion of phagocytic clearance by distinct macrophage phenotypes. Sci Rep. 2016 Aug 1; 6:30663 Epub 2016 Aug 01
    View PubMed
  63. Yushi Q, Li Z, Von Roemeling CA, Doeppler H, Marlow LA, Kim BY, Radisky DC, Storz P, Copland JA, Tun HW. Osteopontin is a multi-faceted pro-tumorigenic driver for central nervous system lymphoma. Oncotarget. 2016 May 31; 7 (22):32156-71
    View PubMed
  64. Qie Y, Yuan H, von Roemeling CA, Chen Y, Liu X, Shih KD, Knight JA, Tun HW, Wharen RE, Jiang W, Kim BY. Surface modification of nanoparticles enables selective evasion of phagocytic clearance by distinct macrophage phenotypes. Sci Rep. 2016 May 19; 6:26269
    View PubMed
  65. Gupta E, Accurso J, Sluzevich J, Menke DM, Tun HW. Excellent Outcome of Immunomodulation or Bruton's Tyrosine Kinase Inhibition in Highly Refractory Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type. Rare Tumors. 2015 Dec 29; 7 (4):6067
    View PubMed
  66. Advani P, Starr J, Swaika A, Jiang L, Qiu Y, Li Z, Tun HW. T-Cell/Histiocyte-Rich Large B-Cell Lymphoma Presenting as a Primary Central Nervous System Lymphoma. Rare Tumors. 2015 Dec 29; 7 (4):6084
    View PubMed
  67. Crozier JA, Sher T, Yang D, Swaika A, Foran J, Ghosh R, Tun H, Colon-Otero G, Kelly K, Chanan-Khan A, Ailawadhi S. Persistent Disparities Among Patients With T-Cell Non-Hodgkin Lymphomas and B-Cell Diffuse Large Cell Lymphomas Over 40 Years: A SEER Database Review. Clin Lymphoma Myeloma Leuk. 2015 Oct; 15 (10):578-85 Epub 2015 June 19
    View PubMed
  68. Witzig TE, Reeder C, Han JJ, LaPlant B, Stenson M, Tun HW, Macon W, Ansell SM, Habermann TM, Inwards DJ, Micallef IN, Johnston PB, Porrata LF, Colgan JP, Markovic S, Nowakowski GS, Gupta M. The mTORC1 inhibitor everolimus has antitumor activity in vitro and produces tumor responses in patients with relapsed T-cell lymphoma. Blood. 2015 Jul 16; 126 (3):328-35 Epub 2015 Apr 28
    View PubMed
  69. von Roemeling CA, Marlow LA, Pinkerton AB, Crist A, Miller J, Tun HW, Smallridge RC, Copland JA. Aberrant lipid metabolism in anaplastic thyroid carcinoma reveals stearoyl CoA desaturase 1 as a novel therapeutic target. J Clin Endocrinol Metab. 2015 May; 100 (5):E697-709 Epub 2015 Feb 12
    View PubMed
  70. Reeb AN, Li W, Sewell W, Marlow LA, Tun HW, Smallridge RC, Copland JA, Spradling K, Chernock R, Lin RY. S100A8 is a novel therapeutic target for anaplastic thyroid carcinoma. J Clin Endocrinol Metab. 2015 Feb; 100 (2):E232-42 Epub 2014 Nov 25
    View PubMed
  71. Sluzevich JC, Tun H, Jacks DS, Jiang L. A case of exuberant cutaneous lymphomagenesis in the setting of chronic patch mycosis fungoides. JAAD Case Rep. 2015 Jan; 1 (1):46-8 Epub 2015 Jan 16
    View PubMed
  72. von Roemeling CA, Radisky DC, Marlow LA, Cooper SJ, Grebe SK, Anastasiadis PZ, Tun HW, Copland JA. Neuronal pentraxin 2 supports clear cell renal cell carcinoma by activating the AMPA-selective glutamate receptor-4. Cancer Res. 2014 Sep 1; 74 (17):4796-810 Epub 2014 June 24
    View PubMed
  73. Von Roemeling CA, Marlow LA, Radisky DC, Rohl A, Larsen HE, Wei J, Sasinowska H, Zhu H, Drake R, Sasinowski M, Tun HW, Copland JA. Functional genomics identifies novel genes essential for clear cell renal cell carcinoma tumor cell proliferation and migration. Oncotarget. 2014 Jul 30; 5 (14):5320-34
    View PubMed
  74. Finn L, Tun H. Combined plasma exchange and platelet transfusion in immune-mediated thrombocytopenic emergencies. Transfus Apher Sci. 2013 Dec; 49(3):661-4. Epub 2013 Jul 12.
    View PubMed
  75. Starr JS, Jiang L, Li Z, Qiu Y, Menke DM, Tun HW. CD47 and osteopontin expression in diffuse large B-cell lymphoma with nodal and intravascular involvement. Clin Lymphoma Myeloma Leuk. 2013 Oct; 13 (5):597-601 Epub 2013 June 26
    View PubMed
  76. Larsen JT, Hogan WJ, Micallef IN, Dispenzieri A, Gertz MA, Inwards DJ, Tun HW, Roy V, Geyer SM, Allred JB, Wu W, Ansell SM, Elliott MA, Tefferi A, Porrata LF, Gastineau DA, Lacy MQ, Litzow MR. A phase I/II trial of reduced intensity allogeneic hematopoietic cell transplant for hematologic malignancies using cladribine, thiotepa and rabbit antithymocyte globulin. Leuk Lymphoma. 2013 Aug; 54 (8):1713-8 Epub 2012 Dec 31
    View PubMed
  77. Shanafelt TD, Ramsay AG, Zent CS, Leis JF, Tun HW, Call TG, LaPlant B, Bowen D, Pettinger A, Jelinek DF, Hanson CA, Kay NE. Long-term repair of T-cell synapse activity in a phase II trial of chemoimmunotherapy followed by lenalidomide consolidation in previously untreated chronic lymphocytic leukemia (CLL). Blood. 2013 May 16; 121 (20):4137-41 Epub 2013 Mar 14
    View PubMed
  78. von Roemeling CA, Marlow LA, Wei JJ, Cooper SJ, Caulfield TR, Wu K, Tan WW, Tun HW, Copland JA. Stearoyl-CoA desaturase 1 is a novel molecular therapeutic target for clear cell renal cell carcinoma. Clin Cancer Res. 2013 May 1; 19 (9):2368-80 Epub 2013 Apr 30
    View PubMed
  79. Li Z, Shigeoka D, Caulfield TR, Kawachi T, Qiu Y, Kamon T, Arai M, Tun HW, Yoshimitsu T. An integrated approach to the discovery of potent agelastatin A analogues for brain tumors: Chemical synthesis and biological, physicochemical and CNS pharmacokinetic analyses. MedChemComm. 2013; 4(7):1093-8.
  80. Li Z, Qiu Y, Personett D, Huang P, Edenfield B, Katz J, Babusis D, Tang Y, Shirely MA, Moghaddam MF, Copland JA, Tun HW. Pomalidomide shows significant therapeutic activity against CNS lymphoma with a major impact on the tumor microenvironment in murine models. PLoS One. 2013; 8 (8):e71754 Epub 2013 Aug 05
    View PubMed
  81. Cooper SJ, von Roemeling CA, Kang KH, Marlow LA, Grebe SK, Menefee ME, Tun HW, Colon-Otero G, Perez EA, Copland JA. Reexpression of tumor suppressor, sFRP1, leads to antitumor synergy of combined HDAC and methyltransferase inhibitors in chemoresistant cancers. Mol Cancer Ther. 2012 Oct; 11 (10):2105-15 Epub 2012 July 23
    View PubMed
  82. Marlow LA, von Roemeling CA, Cooper SJ, Zhang Y, Rohl SD, Arora S, Gonzales IM, Azorsa DO, Reddi HV, Tun HW, Doppler HR, Storz P, Smallridge RC, Copland JA. Foxo3a drives proliferation in anaplastic thyroid carcinoma through transcriptional regulation of cyclin A1: a paradigm shift that impacts current therapeutic strategies. J Cell Sci. 2012 Sep 15; 125 (Pt 18):4253-63 Epub 2012 June 20
    View PubMed
  83. Khurana A, Tun HW, Marlow L, Copland JA, Dredge K, Shridhar V. Hypoxia negatively regulates heparan sulfatase 2 expression in renal cancer cell lines. Mol Carcinog. 2012 Jul; 51 (7):565-75 Epub 2011 July 07
    View PubMed
  84. Li Z, Caulfield T, Qiu Y, Copland JA, Tun HW. Pharmacokinetics of bendamustine in the central nervous system: Chemoinformatic screening followed by validation in a murine model. MedChemComm. 2012; 3(12):1526-30.
  85. Li Z, Kamon T, Personett DA, Caulfield T, Copland JA, Yoshimitsu T, Tun HW. Pharmacokinetics of Agelastatin A in the central nervous system. MedChemComm. 2012; 3(2):233-7.
  86. Cooper SJ, Tun HW, Roper SM, Kim Y, Kislinger T, Drake RR, Copland JA. Current status of biomarker discovery in human clear cell renal cell carcinoma. J Mol Biomark Diagn. 2012.
  87. Jiang L, Li Z, Finn LE, Personnet DA, Edenfield B, Foran JM, Jaeckle KA, Reimer R, Menke DM, Ketterling RP, Tun HW. Primary central nervous system B cell lymphoma with features intermediate between diffuse large B cell lymphoma and Burkitt lymphoma. Int J Clin Exp Pathol. 2012; 5 (1):72-6 Epub 2012 Jan 01
    View PubMed
  88. Vishnu P, Jiang L, Cortese C, Menke DM, Tun HW. Plasmacytoma-like posttransplant lymphoproliferative disorder following orthotopic liver transplantation: a case report. Transplant Proc. 2011 Sep; 43(7):2806-9.
    View PubMed
  89. Saurel CA, Personett DA, Edenfield BH, Solberg LA, Jiang L, Menke DM, Tun HW. Molecular analysis of intravascular large B-cell lymphoma with neoangiogenesis. Br J Haematol 2011 Jan; 152 (2):234-6 Epub 2010 Oct 19
    View PubMed
  90. Jiang L, Marlow LA, Cooper SJ, Roemeling CV, Menke DM, Copland JA, Tun HW. Selective central nervous system tropism of primary central nervous system lymphoma. Int J Clin Exp Pathol. 2010 Oct 8; 3 (8):763-7 Epub 2010 Oct 08
    View PubMed
  91. Cooper SJ, Zou H, Legrand SN, Marlow LA, von Roemeling CA, Radisky DC, Wu KJ, Hempel N, Margulis V, Tun HW, Blobe GC, Wood CG, Copland JA. Loss of type III transforming growth factor-beta receptor expression is due to methylation silencing of the transcription factor GATA3 in renal cell carcinoma. Oncogene. 2010 May 20; 29 (20):2905-15 Epub 2010 Mar 08
    View PubMed
  92. Tun HW, Marlow LA, von Roemeling CA, Cooper SJ, Kreinest P, Wu K, Luxon BA, Sinha M, Anastasiadis PZ, Copland JA. Pathway signature and cellular differentiation in clear cell renal cell carcinoma. PLoS One. 2010 May 18; 5 (5):e10696
    View PubMed
  93. Shetty RK, Adams BH, Tun HW, Runyan BR, Menke DM, Broderick DF. Use of rituximab for periocular and intraocular mucosa-associated lymphoid tissue lymphoma. Ocul Immunol Inflamm. 2010 Apr; 18(2):110-2.
    View PubMed
  94. Shanafelt TD, Bowen DA, Venkat C, Slager SL, Zent CS, Kay NE, Reinalda M, Tun H, Sloan JA, Call TG. The physician-patient relationship and quality of life: lessons from chronic lymphocytic leukemia. Leuk Res. 2009 Feb; 33 (2):263-70 Epub 2008 July 25
    View PubMed
  95. Tun HW, McKinney M. Differential gene expressions of central nervous system lymphoma. Blood 3. 2009; Blood. 2009 113:267-268.
  96. Zubair AC, Grant R, Wu W, Tun H, Rivera C, Moreno-Aspitia A, Joyce M, Roy V, Colon-Otero G, Solberg LA. Platelet count is a sensitive predictor of autologous peripheral blood progenitor cell collection yield in previously treated plasma cell disease patients. Transfusion. 2008 Jun; 48 (6):1106-14 Epub 2008 Feb 25
    View PubMed
  97. Tun HW, Personett D, Baskerville KA, Menke DM, Jaeckle KA, Kreinest P, Edenfield B, Zubair AC, O'Neill BP, Lai WR, Park PJ, McKinney M. Pathway analysis of primary central nervous system lymphoma. Blood. 2008 Mar 15; 111 (6):3200-10 Epub 2008 Jan 09
    View PubMed
  98. Zou YS, Fink SR, Stockero KJ, Paternoster SF, Smoley SA, Tun HW, Reeder CB, Tefferi A, Dewald GW. Efficacy of conventional cytogenetics and FISH for EGR1 to detect deletion 5q in hematological disorders and to assess response to treatment with Lenalidomide. Leuk Res. 2007 Sep; 31 (9):1185-9 Epub 2006 Nov 27
    View PubMed
  99. Tun HW, Wallace KH, Grinton SF, Khoor A, Burger CD. Etanercept therapy for late-onset idiopathic pneumonia syndrome after nonmyeloablative allogeneic hematopoietic stem cell transplantation. Transplant Proc. 2005 Dec; 37(10):4492-6.
    View PubMed
  100. Tun HW, Krishna M, Menke DM. Hepatitis C-related posttransplant plasma cell proliferative disorder with hepatitis C virus in neoplastic plasma cells: a new posttransplant disease entity? Transplant Proc. 2004 Nov; 36(9):2692-6.
    View PubMed
  101. Tun H, Marlow L, Pinnix I, Kinsey R, Sambamurti K. Lipid rafts play an important role in A beta biogenesis by regulating the beta-secretase pathway. J Mol Neurosci. 2002 Aug-Oct; 19 (1-2):31-5
    View PubMed
  102. Pinnix I, Musunuru U, Tun H, Sridharan A, Golde T, Eckman C, Ziani-Cherif C, Onstead L, Sambamurti K. A novel gamma -secretase assay based on detection of the putative C-terminal fragment-gamma of amyloid beta protein precursor. J Biol Chem. 2001 Jan 5; 276 (1):481-7
    View PubMed
  103. Sambamurti K, Pinnix I, Onstead L, Tun H, Younkin LH, Younkin SG. Role of GPI-anchored proteins in beta-secretase processing. Neurobiology of Aging. 2000; 21:257.